Healthy Living

Trovagene Shows Promising Data for Lymphoma Treatment

Trovagene Shows Promising Data for Lymphoma Treatment

Trovagene is a clinical stage biotechnology company that focuses on developing therapeutics for blood cancers and solid tumor malignancies, and they’ve just shown some preclinical data that has boosted their shares by 3%. The data is showing that a medication called PCM 075 in combination with an HDAC inhibitor showed “significant synergy of up to 80%” in aggressive double-hit beta-cell-lymphoma (DLBCL) and mantel-cell-lymphoma lines (two types of non-Hodgkin lymphoma cell lines).

But what on Earth does all of this mean?